Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 01, 2022 07:41 ET | Source: Genmab A/S

Transactions in connection with share buy-back program

Company Announcement COPENHAGEN, Denmark; August 1, 2022 – Genmab A/S (Nasdaq: GMAB). On June 17, 2022 Genmab announced the initiation of a share buy-back program to mitigate dilution from warrant...
July 25, 2022 07:50 ET | Source: Genmab A/S

Transactions in connection with share buy-back program

Company Announcement COPENHAGEN, Denmark; July 25, 2022 – Genmab A/S (Nasdaq: GMAB). On June 17, 2022 Genmab announced the initiation of a share buy-back program to mitigate dilution from warrant...
July 20, 2022 13:03 ET | Source: Genmab A/S

Major Shareholder Announcement

Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; July 20, 2022 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital...
July 19, 2022 06:33 ET | Source: Genmab A/S

Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2022

Company Announcement Net sales of DARZALEX® in the second quarter of 2022 totaled USD 1,986 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN,...
July 18, 2022 10:01 ET | Source: Genmab A/S

Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Company Announcement COPENHAGEN, Denmark; July 18, 2022 – Genmab A/S (Nasdaq: GMAB) today announced that AbbVie (NYSE: ABBV) will submit a conditional marketing authorization application (MAA) with...
July 18, 2022 07:27 ET | Source: Genmab A/S

Transactions in connection with share buy-back program

Company Announcement COPENHAGEN, Denmark; July 18, 2022 – Genmab A/S (Nasdaq: GMAB). On June 17, 2022 Genmab announced the initiation of a share buy-back program to mitigate dilution from warrant...
July 11, 2022 11:28 ET | Source: Genmab A/S

Major Shareholder Announcement

Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; July 11, 2022 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital...
July 11, 2022 04:50 ET | Source: Genmab A/S

Transactions in connection with share buy-back program

Company Announcement COPENHAGEN, Denmark; July 11, 2022 – Genmab A/S (Nasdaq: GMAB). On June 17, 2022 Genmab announced the initiation of a share buy-back program to mitigate dilution from warrant...
July 05, 2022 14:05 ET | Source: Genmab A/S

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; July 5, 2022 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 10,992 shares as a consequence of the exercise of employee warrants. The...
July 04, 2022 04:16 ET | Source: Genmab A/S

Transactions in connection with share buy-back program

Company Announcement COPENHAGEN, Denmark; July 4, 2022 – Genmab A/S (Nasdaq: GMAB). On June 17, 2022 Genmab announced the initiation of a share buy-back program to mitigate dilution from warrant...